WHAT IS CLAIMED IS:

1. A method for aerosolizing a dose of insulin,

25

- 2 said method comprising:
- 3 providing insulin as a dry powder;
- dispersing an amount of the dry powder in a gas
- 5 stream to form an aerosol; and
- 6 capturing the aerosol in a chamber having a
- 7 mouthpiece for subsequent inhalation by a patient.
- 1 2. A method as in claim 1, wherein the insulin is
- 2 substantially free from penetration enhancers.
- 1 3. A method as in claim 1, wherein the insulin is
- 2 present in a dry powder carrier at a weight concentration in
- 3 the range from about 5% to 99%.
- 1 4. A method as in claim 3, wherein the powder
- 2 carrier comprises a carbohydrate, organic salt, amino acid,
- 3 peptide, or protein.
- 5. A method as in claim 1, wherein the insulin dry
- 2 powder comprises particles having an average size below 10 μ m.
- 1 6. A method as in claim 1, wherein the dry powder
- 2 comprises individual particles including both insulin and a
- 3 carrier material.
- 7. A method a in claim 6, wherein the insulin is
- 2 present in the individual particles at from 5% to 99% by
- 3 weight.
- 8. An improved method for the respiratory delivery
- 2 of insulin, wherein the improvement comprises delivering the
- 3 insulin as a dry powder.
- 9. An improved method as in claim 8, wherein the
- 2 insulin is substantially free from penetration enhancers.

- 1 10. An improved method as in claim 8, wherein the
- 2 insulin is present in a dry powder carrier at a weight
- 3 concentration in the range from about 10% to 99%.
- 1 11. An improved method as in claim 10, wherein the
- 2 powder carrier comprises a carbohydrate, organic salt, amino
- 3 acid, peptide, or protein.
- 1 12. An improved method as in claim 8, wherein the
- 2 insulin dry powder comprises particles having an average size
- 3 below 10 μ m.
- 1 13. An improved method as in claim 8, wherein the
- 2 dry powder comprises individual particles including both
- 3 insulin and a carrier material.
- 1 14. An improved method as in claim 13, wherein the
- 2 insulin is present in the individual particles at from 5% to
- 3 99% by weight.
- 1 15. A method for preparing a stable, dry powder
- insulin composition, said method comprising:
- dissolving insulin in an aqueous buffer to form a
- 4 solution; and
- 5 spray drying the solution to produce substantially
- 6 amorphous particles having an average size below 10 μ m.
- 16. A method as in claim 15, wherein the insulin is
- 2 dissolved in a aqueous buffer together with a pharmaceutical
- 3 carrier, wherein a dry powder having insulin present in
- 4 individual particles at from 5% to 99% by weight is produced
- 5 upon spray drying.
- 1 17. A method as in claim 16, wherein the
- 2 pharmaceutical carrier is a carbohydrate, organic salt, amino
- acid, peptide, or protein which produces a powder upon spray
- 4 drying.

- 1 18. A method as in claim 17, wherein the
- 2 carbohydrate is selected from the group consisting of
- mannitol, raffinose, lactose, malto dextrin and trehalose.
- 1 19. A method as in claim 17, wherein the organic
- 2 salt is selected from the group consisting of sodium citrate,
- 3 sodium acetate, and sodium ascorbate.
- 1 20. An insulin composition for pulmonary delivery,
- 2 said composition comprising individual particles which include
- 3 insulin present at from 5% to 99% by weight in a
- 4 pharmaceutical carrier material and have a size below 10 μ m.
- 1 21. An insulin composition as in claim 20, wherein
- the composition is substantially free from penetration
- 3 enhancers.
- 1 22. An insulin composition as in claim 20, wherein
- 2 the pharmaceutical carrier material comprises a carbohydrate
- 3 selected from the group consisting of mannitol, raffinose,
- 4 lactose, malto dextrin, and trehalose.
- 1 23. An insulin composition as in claim 20, wherein
- 2 the pharmaceutical carrier material comprises an organic salt
- 3 selected from the group consisting of sodium citrate, sodium
- 4 gluconate, and sodium ascorbate.
- 1 24. An insulin composition produced by the method
- 2 of claim 15.
- 1 25. An insulin composition consisting essentially
- of dry powder insulin having an average particle size below
- 3 10 μ m.